Cargando…
Thyrotoxicosis in patients with a history of Graves’ disease after SARS-CoV-2 vaccination (adenovirus vector vaccine): Two case reports
BACKGROUND: Vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which were approved for emergency use have been administered on a large scale globally to contain the pandemic coronavirus disease 2019 (COVID-19) and to save lives. Vaccine safety is one of the issues under su...
Autores principales: | Yan, Bo-Chang, Luo, Rong-Rong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9979287/ https://www.ncbi.nlm.nih.gov/pubmed/36874429 http://dx.doi.org/10.12998/wjcc.v11.i5.1122 |
Ejemplares similares
-
Graves’ Thyrotoxicosis Following SARS-CoV-2 Infection
por: Harris, Asaf, et al.
Publicado: (2020) -
SARS-CoV-2 vaccination related hyperthyroidism of Graves’ disease
por: Shih, Shyang-Rong, et al.
Publicado: (2022) -
Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine
por: Kennedy, Richard B
Publicado: (2022) -
The Effect of Inactivated SARS-CoV-2 Vaccines on TRAB in Graves’ Disease
por: Huang, LingHong, et al.
Publicado: (2022) -
Aggravation of hyperthyroidism after heterologous prime-boost immunization with inactivated and adenovirus-vectored SARS-CoV-2 vaccine in a patient with Graves’ disease
por: Sriphrapradang, Chutintorn
Publicado: (2021)